publication . Article . 2017

Development and validation of an LC‐MS/MS method to quantify lysergic acid diethylamide (LSD), iso‐LSD, 2‐oxo‐3‐hydroxy‐LSD, and nor‐LSD and identify novel metabolites in plasma samples in a controlled clinical trial

Patrick C. Dolder; Matthias E. Liechti; Katharina M. Rentsch;
Open Access
  • Published: 26 May 2017 Journal: Journal of Clinical Laboratory Analysis, volume 32, page e22265 (issn: 0887-8013, Copyright policy)
  • Publisher: Wiley
  • Country: Switzerland
Abstract
Background Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of this study was to develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantification of LSD, iso-LSD, 2-oxo-3-hydroxy LSD (O-H-LSD), and nor-LSD in plasma samples from 24 healthy subjects after controlled administration of 100 μg LSD in a clinical trial. In addition, metabolites that have been recently described in in vitro studies, including lysergic acid monoethylamide (LAE), lysergic acid ethyl-2-hydroxyethylamide (LEO), 2-oxo-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD, should be identified. Methods Separation of LSD and its ...
Subjects
free text keywords: Detection limit, Chemistry, Reversed-phase chromatography, Liquid chromatography–mass spectrometry, Matrix (chemical analysis), 2-oxo-3-hydroxy-LSD, Lysergic acid diethylamide, medicine.drug, medicine, Lysergic acid, chemistry.chemical_compound, Chromatography
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2017

Development and validation of an LC‐MS/MS method to quantify lysergic acid diethylamide (LSD), iso‐LSD, 2‐oxo‐3‐hydroxy‐LSD, and nor‐LSD and identify novel metabolites in plasma samples in a controlled clinical trial

Patrick C. Dolder; Matthias E. Liechti; Katharina M. Rentsch;